- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Good
|
- 10-Q Quarterly report
- 10.1 3010 Second Amendment
- 10.2 3033 Lease Agreement
- 10.3 3033 First Amendment
- 10.4 3033 Second Amendment
- 10.5 3033 Third Amendment
- 10.6 3033 Fourth Amendment
- 10.7 3033 Fifth Amendment
- 10.8 3033 Sixth Amendment
- 10.9 Termination Agreement
- 10.10 Termination Agreement Second Amendment
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Exhibit 32.2
CERTIFICATIONS OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Singular Genomics Systems, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dalen Meeter, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: November 14, 2023 | By: | /s/ Dalen Meeter | |
Dalen Meeter | |||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |